Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

OPK earnings analysis

Filed August 28, 2026 · Our reading of the company's report

The latest report

OPKO’s 2026 Q2 results showed a strong sequential recovery: revenue rose to approximately $164 million, gross margin reached 48.9%, operating margin improved to negative 15.3%, and diluted EPS improved to negative…

Read full summary

OPKO’s 2026 Q2 results showed a strong sequential recovery: revenue rose to approximately $164 million, gross margin reached 48.9%, operating margin improved to negative 15.3%, and diluted EPS improved to negative $0.01. However, free cash flow remained negative at $47 million and worsened from Q1, tempering the operating improvement. Liquidity was $314.4 million, but foreign-currency exposure increased to 33.3% of six-month revenue and the company had $9.6 million outstanding under certain credit lines. No material changes to previously disclosed 10-K risk factors were reported, and no quantitative guidance was provided.

Read the original on SEC.gov

Gross and operating margin

How much of each revenue dollar the business keeps.

49% Gross margin Operating margin Jul 2025 Aug 2026

One point per quarterly or annual filing. Both margins are shares of that report's revenue.

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $51 Operating expenses $64 Left as operating profit $-15

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish Mar 2025 Aug 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

Reported figures

Earnings per share
$-0.01

What stood out

  • Revenue rebounded sharply sequentially

    Revenue increased to approximately $164 million in 2026 Q2 from $124 million in Q1, up about 32%, and from $157 million in the prior-year quarter, up about 4%.

  • Margins improved materially

    Gross margin expanded to 48.9% from 36.8% in Q1 and 31.5% in 2025 Q2, while operating margin improved to negative 15.3% from negative 41.1% and negative 38.3%, respectively.

  • EPS loss narrowed

    Diluted EPS improved to negative $0.01 from negative $0.07 in Q1 and negative $0.19 in the prior-year quarter.

  • Liquidity remained substantial

    Cash, cash equivalents and restricted cash totaled $314.4 million at June 30, 2026; the company reported a weighted-average cash interest rate of approximately 1.6% for the six months ended June 30, 2026.

  • Controls remained effective

    Management stated that disclosure controls were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, financial reporting during the quarter.

What to watch

  • Cash burn worsened sequentially

    Free cash flow was negative $47 million in 2026 Q2, compared with negative $21 million in Q1, indicating continued cash consumption despite the operating-margin improvement.

  • Greater foreign-exchange exposure

    Foreign-currency exposure increased: 33.3% of six-month revenue was denominated in currencies other than the U.S. dollar versus 24.5% in the comparable 2025 period. Gross accumulated currency translation adjustments rose to $25.0 million from $17.6 million at December 31, 2025.

  • Borrowing and rate exposure

    The company had $9.6 million of aggregate principal outstanding under its Chilean and Spanish lines of credit at a weighted-average interest rate of approximately 5.5%; it also stated that it does not currently hedge interest-rate exposure.

  • No formal risk-factor changes

    The filing states that there were no material changes to the risk factors previously disclosed in the Form 10-K; therefore, no formal risk-factor update was identified. The 10-Q nevertheless quantifies foreign-currency exposure at 33.3% of six-month revenue.

Management's outlook

The 10-Q does not provide explicit numeric revenue or EPS guidance; outlook was not quantified in the extracted MD&A.

Earlier filings 4

10-Q · August 28, 2026

OPKO delivered a strong quarterly rebound, with revenue of $163.5 million, gross margin of 48.9%, operating margin of negative 15.3%, and diluted EPS of negative $0.01. Revenue, margin, and EPS improved substantially…

10-Q · July 27, 2026

OPKO delivered Q2 revenue of $163.580 million and a diluted loss per share of $0.01, with gross margin improving to 48.9% and operating loss narrowing to $6.972 million. The improvement was driven by Pharmaceuticals,…

10-Q · April 28, 2026

OPKO reported total revenue of $124.196 million for Q1 2026, down $25.756 million (‑17%) versus Q1 2025, driven largely by the September 2025 divestiture of oncology assets. Operating loss narrowed to $51.017 million…

10-K · February 26, 2026

OPKO's 2025 10-K emphasizes a two‑pillar business: pharmaceuticals (NGENLA®, Rayaldee, ModeX pipeline) and diagnostics (BioReference after strategic divestitures). Management highlights pipeline progress (ModeX…

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.